Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
June 01 2022 - 08:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced that Pablo J. Cagnoni, M.D.,
president and chief executive officer, will participate in a
fireside chat at the Jefferies Global Healthcare Conference on
Thursday, June 9, 2022, at 2:30 p.m. EDT.
A live audio webcast will be available within the Investors
& Media section of the Rubius Therapeutics website. An archived
replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was named among the 2021 Top Places to
Work in Massachusetts by the Boston Globe, and its manufacturing
site was recently named 2022 Best Places to Work in Rhode
Island by Providence Business News. For more information,
visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us
on Facebook.
Contacts:InvestorsLori Murray,
Chief Corporate Affairs Officerlori.murray@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2023 to Mar 2024